RX 515 (Amoxicillin 250 mg)
Pill with imprint RX 515 is Pink, Round and has been identified as Amoxicillin 250 mg. It is supplied by Ranbaxy Pharmaceuticals Inc..
Amoxicillin is used in the treatment of bacterial infection; urinary tract infection; chlamydia infection; bacterial endocarditis prevention; anthrax prophylaxis (and more), and belongs to the drug class aminopenicillins. There is no proven risk in humans during pregnancy. Amoxicillin 250 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for RX 515
Amoxicillin
- Imprint:
- RX 515
- Strength:
- 250 mg
- Color:
- Pink
- Size:
- 18.00 mm
- Shape:
- Round
- Availability:
- Prescription only
- Drug Class:
- Aminopenicillins
- Pregnancy Category:
- B - No proven risk in humans
- CSA Schedule:
- Not a controlled drug
- Labeler / Supplier:
- Ranbaxy Pharmaceuticals Inc.
- Inactive Ingredients:
- aspartame
compressible sugar
corn starch
FD&C Red No. 40 Aluminium Lake
magnesium stearate
mannitol
strawberry guarana flavor
magnesium silicate
Note: Inactive ingredients may vary.
More about amoxicillin
- Amoxicillin Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Compare Alternatives
- Support Group
- Pricing & Coupons
- En Español
- 164 Reviews – Add your own review/rating
- Drug class: aminopenicillins
Consumer resources
- Amoxicillin
- Amoxicillin Capsules and Tablets
- Amoxicillin Chewable Tablets
- Amoxicillin Extended-Release Tablets
- Amoxicillin Suspension
- Amoxicillin (Advanced Reading)
Other brands: Amoxil, Trimox, Moxatag, Amoxicot, ... +3 more
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2018 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
